Inclusion Criteria:

• Histologically proven recurrent meningioma or intracranial hemangiopericytoma or hemangioblastoma. This includes benign, atypical, or malignant meningioma; patients with neurofibromatosis type 1 or 2
• Patients with classic radiographic picture of meningioma may also enroll if not surgically accessible
• Unequivocal evidence for tumor progression by MRI
• Steroids dosing - malignant meningiomas must be on stable dose for at least 5 days prior to baseline imaging.
• Recent resection for recurrent tumor - patients will be eligible as long as they have recovered from the effects of surgery and have residual disease that can be evaluated.
• Prior radiation therapy
• Patients who have not had prior surgery or radiotherapy for their meningioma will be reviewed at multidisciplinary brain tumor conference including neurosurgery and radiation oncology to determine that the patient is appropriate for this study
• Prior therapy: There is no limitation on the number of prior surgeries, radiation therapy, radiosurgery treatments, or chemotherapy.
• All patients must sign an informed consent indicating that they are aware of the investigational nature of the study.
• Age ≥ 18 years old
• Karnofsky performance status ≥ 60%.
• ≥ 4 weeks since prior RT, stereotactic radiosurgery, or chemotherapy.
• Required Initial Laboratory Values
• Patients with a history of NF may have other stable CNS tumors, such as schwannoma, acoustic neuroma, or ependymoma, but ONLY if these lesions have been stable in size for the preceding 6 months.

Exclusion Criteria:

• Patients with the history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix, unless in complete remission and off all therapy for the disease for a minimum of 3 years) are ineligible.
• Any prior TKI therapy (SU011248, Sorafenib, Semaxinib, Axitinib)
• Concomitant use of any other investigational drugs
• Concomitant use of enzyme-inducing anti-epileptic drugs.
• Concomitant use of St John's Wort.
• Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
• Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade ≥ 2.
• Prolonged QTc interval on baseline EKG (>450 msec for males and >470 msec for females).
• Uncontrolled hypertension (>150/100 mm Hg despite optimal medical therapy).
• History of intracranial hemorrhage.
• Pre-existing thyroid abnormality, with thyroid function tests that cannot be maintained in the normal range with medication.
• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection.
• Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. QOL, are allowed.
• Ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg daily for thromboembolic prophylaxis is allowed).
• Pregnancy or breast-feeding. Patients must be surgically sterile, postmenopausal, or agree to use effective contraception during the period of therapy